news
European Commission grants first-of-a-kind biosimilar approval
The approval means Sandoz’s Wyost® and Jubbonti® are the first…
The approval means Sandoz’s Wyost® and Jubbonti® are the first biosimilars of denosumab authorised in Europe.
List view / Grid view
Claire D'Abreu Hayling
news
Sandoz to file for approval of aflibercept biosimilar
Sandoz intends to seek regulatory approval for its aflibercept biosimilar…
Sandoz intends to seek regulatory approval for its aflibercept biosimilar in the US and EU in the coming months.
news
Sandoz to build Slovenian biosimilar development facility
A planned investment of approximately $90 million will help build…
A planned investment of approximately $90 million will help build Sandoz’s new Slovenia-based biopharma biosimilar development facility by 2026.
